Isomorphic Labs, the London-based company that uses artificial intelligence to design medicines, announced on Tuesday, 17 November, that it has raised $5 billion in a Series C funding round. The company, led by Nobel laureate Sir Demis Hassabis, said the money will help move its first drug candidates towards clinical trials.

In its announcement, Isomorphic said the round was co-led by investment firms Greenoaks and Sequoia Capital and was oversubscribed. Andreessen Horowitz (a16z) and several other new investors joined, and Alphabet continued what the company called a "significant investment".

Who has invested

According to the company, all its existing investors took part in the round. It named them as:

  • Thrive Capital
  • MGX
  • GV and CapitalG
  • Temasek
  • the UK Sovereign AI Fund

Isomorphic did not state the valuation at which the money was raised. Technology news site TechCrunch noted that Bloomberg had reported earlier this month that the company was seeking funds at a valuation of $50 billion; the company's statement does not confirm that figure. TechCrunch also reported that the new round follows a $2.1 billion Series B raised in May this year.

What the company does

Isomorphic Labs was founded in 2021. TechCrunch describes it as a spin-out of Google's DeepMind whose work builds on AlphaFold, the AI system that predicts the three-dimensional structure of proteins and for which Hassabis and John Jumper won the Nobel Prize in Chemistry.

The company's main product is what it calls a drug design engine, or IsoDDE. It said the engine brings together a set of AI simulation models that work across several disease areas and types of drugs, and that it searches very large "chemical spaces" to help scientists design and refine candidate molecules.

Isomorphic said this work is "yielding positive preclinical results" in its own programmes in oncology (cancer) and immunology, and in projects with partners. Preclinical results come before testing in people; the company has not yet announced a drug in human trials, and said the results are "setting the stage for clinical entry". According to TechCrunch, the company has deals with drugmakers Eli Lilly, Novartis and Johnson & Johnson.

Where the money will go

The company said the proceeds will be used to:

  • further develop IsoDDE and build more advanced models of biology;
  • create a network of partners to better understand how diseases work;
  • build global infrastructure for what it calls AI-led bioengineering;
  • build translational and clinical development capabilities as its drug candidates advance to clinical trials.
"Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients," Hassabis, the company's founder and chief executive, said in the statement.

Max Jaderberg, the company's president, said its teams combine machine learning researchers with experienced "drug hunters". Neil Mehta, founder and managing partner of Greenoaks, described discovering new medicines as "an optimization challenge of almost infinite scale", while Sequoia Capital partner Konstantine Buhler said that using AI to improve human health is "one of the most important challenges of our generation".

What is not yet known

The announcement does not give a timeline for the first clinical trial, name the diseases or molecules that will be tested first, or say how much each investor has put in. The claims about the engine's precision and the preclinical results are the company's own and have not been independently verified in the announcement.

Isomorphic Labs is headquartered in London and has offices in Cambridge, Massachusetts, and Lausanne, Switzerland.

PS